Beckman Coulter Shares Drop on Troponin Test Issues

Beckman Coulter's shares dropped around 7 percent after the firm disclosed that an ongoing issue surrounding its troponin test kits could lead to further restrictions on the test and may have a material impact on its results.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories